Information:
Fel:
ID
34554
Beskrivning
An Observational Study on The Safety and Effectiveness of Mabthera (Rituximab) in The First Six Months of Treatment in Patients With Severe Active Rheumatoid Arthritis; ODM derived from: https://clinicaltrials.gov/show/NCT01071798
Länk
https://clinicaltrials.gov/show/NCT01071798
Nyckelord
Versioner (1)
- 2019-01-19 2019-01-19 -
Rättsinnehavare
see on clinicaltrials.gov
Uppladdad den
19 januari 2019
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Rheumatoid Arthritis NCT01071798
Eligibility Rheumatoid Arthritis NCT01071798
- StudyEvent: Eligibility
Similar models
Eligibility Rheumatoid Arthritis NCT01071798
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
ID.1
Item
adult patients, >/= 18 years of age
boolean
ID.2
Item
severe active rheumatoid arthritis; eligible for treatment with rituximab according to current spc
boolean
ID.3
Item
informed consent to data collection
boolean
ID.4
Item
ongoing contraception (for female patients only)
boolean
ID.5
Item
previous treatment with rituximab (mabthera)
boolean
ID.6
Item
allergy against monoclonal antibodies, respectively chimeric monoclonal antibodies
boolean
ID.7
Item
active severe infection
boolean
ID.8
Item
severe heart failure (nyha class iv) or severe, uncontrolled cardiac disease
boolean
ID.9
Item
treatment in other studies within 3 months before rituximab therapy
boolean
ID.10
Item
pregnancy or breast feeding
boolean